CRISPR trials are about to begin in people—but we still don’t know how well it works in monkeys – MIT Technology Review
MIT Technology Review |
CRISPR trials are about to begin in people—but we still don’t know how well it works in monkeys
MIT Technology Review Some of the first CRISPR experiments in monkeys involve blood disorders like sickle-cell disease and beta thalassemia. CRISPR could be ideal for both diseases, scientists think, because each is caused by mutations in a single gene that makes hemoglobin … Why FDA’s proposed gene-editing regulations could stifle CRISPR research on food animalsGenetic Literacy Project Can the Gene-Editing Technology CRISPR Cure This Debilitating Brain Disease?Brinkwire (press release) |
STAT |
Biogen and the badly needed gene therapy acquisition that got away
STAT ast July, Biogen (BIIB 1) executives unveiled a new, more aggressive business development plan. Cash thrown off by the biotech’s maturing but still very profitable multiple sclerosis franchise would be redeployed to license or acquire new neuroscience … |
|
Biotech Analysis Central Pharma News: Novartis’s Gene Therapy Catch, AstraZeneca’s NASH Move, Clovis’s …
Seeking Alpha The biggest reason for the deal was because of AveXis knowledge in gene therapy. In addition, AveXis’s main clinical candidate is AVXS-101 treats spinal muscular atrophy (SMA), which is a rare disease that affects the motor nerve cells in the spinal … |
Proactive Investors Australia |
Cynata Therapeutics granted another patent for its unique stem cell technology
Proactive Investors Australia Cynata Therapeutics Ltd (ASX:CYP) has been granted a further patent covering aspects of its proprietary Cymerus™ stem cell platform by the U.S. Patent and Trademark Office (USPTO). The patent covers certain proprietary methods relating to the platform … Cynara’s stem cell technology platform granted new US patentManufacturers’ Monthly |